Document Detail


Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar rats.
MedLine Citation:
PMID:  17105425     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the study was to investigate the possibility to increase the therapeutic gain of the cytotoxic agent, cisplatin, by incorporation of radioactive platinum. In this study, we investigated how organs at risk (i.e., kidneys, bone marrow, and liver) are affected by treatment with 191Pt-cisplatin, compared to treatment with conventional cisplatin. Rats (total, n = 69) were divided into three groups and given 5 mg/kg 191Pt-cisplatin and 5 mg/kg nonradioactive cisplatin or saline. The weight of the animals and blood samples, including analysis of creatinine, bilirubin, alanine and aspartate aminotransferases and platelet count, was followed for 6 weeks after treatment. Histopathology examinations of kidney and liver tissues were performed. An initial decrease in weight gain was seen from 3 days after treatment with cisplatin and 191Pt-cisplatin and for 1 week onward; thereafter, the weight gain continued, following the same pattern as for the control group. Concentration of plasma creatinine was increased for both cisplatin groups but with no significant difference between treatment groups. No other significant differences in effect parameters were found. There was no increase in toxicity for radioactive cisplatin on liver, kidneys, and bone marrow, compared to conventional cisplatin. Further experimental and clinical studies on preparations of this type are thus warranted.
Authors:
Kristina Norrgren; Maria Sjölin; Sven Björkman; Johan Areberg; Anders Johnsson; L Johansson; Sören Mattsson
Related Documents :
1906845 - Activities of purine catabolism related enzymes in zinc deficiency: relationship to t-l...
16999025 - Long term excessive zn-supplementation promotes metabolic syndrome-x in wistar rats fed...
11527655 - Low dietary zinc alters indices of copper function and status in postmenopausal women.
11604475 - Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by re...
21091545 - Effect of dietary fish oil on milk yield, fatty acids content and serum metabolic profi...
22063275 - Growth, carcass and meat characteristics of karayaka growing rams fed sugar beet pulp, ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer biotherapy & radiopharmaceuticals     Volume:  21     ISSN:  1084-9785     ISO Abbreviation:  Cancer Biother. Radiopharm.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-11-19     Completed Date:  2007-03-20     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9605408     Medline TA:  Cancer Biother Radiopharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  528-34     Citation Subset:  IM    
Affiliation:
Department of Radiation Physics, Malmö University Hospital, Malmö, Sweden. Kristina.Norrgren@med.lu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bone Marrow Diseases / chemically induced
Cisplatin / toxicity*
Drug-Induced Liver Injury
Female
Kidney Diseases / chemically induced
Platinum / toxicity*
Radioisotopes / toxicity*
Random Allocation
Rats
Rats, Wistar
Chemical
Reg. No./Substance:
0/Radioisotopes; 15663-27-1/Cisplatin; 7440-06-4/Platinum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lanthanide-loaded liposomes for multimodality imaging and therapy.
Next Document:  The diagnostic role of radioactivity in sentinel nodes in oral and oropharyngeal cancer.